Background: Plasma renin activity (PRA), measured under controlled conditions, is a marker of the degree and persistence of renin-angiotensin system blockade.
A ngiotensin (Ang) II receptor blockers (ARBs), including olmesartan medoxomil, valsartan, and irbesartan, lower blood pressure (BP) by antagonizing the binding of Ang II to the type 1 (AT 1 ) receptor. Some ARBs exhibit varying degrees of insurmountable binding to the AT 1 receptor, whereas others display surmountable binding characteristics. 1 Receptor blockade by surmountable ARBs (eg, losartan potassium) can be reversed with increasing concentrations of Ang II, whereas insurmountable ARBs (eg, olmesartan, irbesartan, and valsartan) bind more tightly to the AT 1 receptor and are less likely to be overcome by increased levels of Ang II. 1, 2 In persons with a normally functioning renin-angiotensin system (RAS), blockade of the AT 1 receptor tends to lower BP and induce a compensatory rise in plasma renin activity (PRA). In vivo changes in PRA were used to quantitatively assess the degree and persistence of RAS blockade by Ang II receptor antagonists, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] angiotensinconverting enzyme inhibitors, 3, 4, 6, 9, [13] [14] [15] and renin inhibitors. 10, 16 Most studies were performed under conditions not normally used in clinical practice, such as after mild sodium depletion, 3, 4, 10, 11, 15 sodium loading, 9 overnight fast, 10, 12 controlled recumbency, 3,4,9 -11,15 or supine position. 7, 8, 13 In one such study, 12 we showed that single doses of olmesartan (5, 20 and 40 mg) induced a dose-dependent rise in mean PRA levels. Here, we report on two similarly designed studies in which PRA was measured under normal clinic conditions, and the PRA response to AT 1 receptor blockade was compared between subjects with low (Ͻ0.65 ng/mL/h) and normal/high (Ն0.65 ng/mL/h) baseline PRA levels. Blood samples were drawn from subjects on unrestricted diets who were allowed normal ambulatory activity and then were asked to sit quietly during blood drawing. The studies compared changes in PRA and urinary aldosterone excretion (UAE) over 24 h. Study CS866-445 tested single doses of placebo and olmesartan 20 and 40 mg or valsartan 80 and 160 mg. Study CS866-448 tested olmesartan 40 mg, irbesartan 300 mg, or valsartan 160 and 320 mg.
Methods

Study Design
The two studies described here are CS866-445 and CS866-448 (clinicaltrials.gov identifier NCT00185055), consisting of a 2-week screening phase, followed by a randomized, observer-blinded, 10-sequence, crossover treatment period lasting 5 weeks.
During the second phase, subjects received single, oral doses of study medication on five occasions according to a predetermined randomization schedule, with a 7-day washout period between occasions. In Study CS866-445, olmesartan 20 mg, olmesartan 40 mg, valsartan 80 mg, valsartan 160 mg, and placebo were compared. In Study CS866-448, olmesartan 40 mg, irbesartan 300 mg, valsartan 160 mg, valsartan 320 mg, and placebo were compared. Doses were administered at the same time of day (Ϯ90 min).
At screening, blood and urine samples were collected for serum chemistries, hematology, routine urinalysis, pregnancy testing, and alcohol and drug screening. Serum chemistries, hematology, and routine urinalysis were repeated in all subjects 24 h after the final dose.
Subjects reported to the clinic approximately 24 h before dosing. Blood samples were collected predose (time 0) and at 2, 4, 8, and 24 h after drug administration. In Study CS866-445, blood samples were also collected at 16 h postdose. Heart rate and seated cuff BP were measured before each blood draw. After BP measurements, subjects walked around for 5 min, and then were seated for blood sampling. Subjects voided prior to drug administration, after which, 24-h urine collection commenced. After completion of urine collection and 24-h blood sampling, subjects left the facility.
Nutrient or sodium intakes were not modified before or during the study. Likewise, subjects were not prescreened for PRA or factors such as race, age, or sex that might be associated with renin status.
The study protocol was approved by the Institutional Review Board of MDS Pharma Service (Neptune, NJ) and conducted in accordance with current Good Clinical Practice, International Conference on Harmonization Tripartite Guidelines, and the Declaration of Helsinki. Subjects gave written, informed consent.
Subjects
The planned enrollment in both trials comprised 20 healthy volunteers, 18 to 65 years of age. Subjects were required to be healthy, and women were included only if they were not pregnant or breastfeeding and were using an acceptable method of birth control.
Exclusion criteria comprised any serious cardiovascular, renal, pulmonary, hepatic, gastrointestinal, uncontrolled endocrine/metabolic, hematologic/oncologic, neurologic, or psychiatric diseases; a history of drug or alcohol abuse; positive testing for human immunodeficiency virus, hepatitis B, or hepatitis C; history of an allergic response to any ARB; and abnormal fasting laboratory values that might compromise a subject's safety. Prescription drugs were not permitted (except for oral contraceptives and postmenopausal hormone replacement therapy) within 14 days of dose administration, nor were nonprescription drugs permitted (except for vitamins) within 7 days of dose administration, unless the subject had been on a stable dose for Ն3 months before screening.
Efficacy and Safety Assessments
The primary efficacy variable in both studies was mean change in PRA from predose to 24 h postdose (⌬PRA 24 ). Secondary variables included 24-h UAE. The PRA was measured by an enzyme kinetic method with quantification of Ang I by radioimmunoassay. 17 Angiotensin I was generated for 3 h. For samples with PRA Ͻ1.0 ng/mL/h, Ang I generation was repeated for 18 h. The UAE was measured by radioimmunoassay (ICN Biomedicals, now MP Biomedicals, Irvine, CA). Safety variables included adverse events (AEs), physical examinations, clinical laboratory tests, BP, and heart rate.
Statistical Analyses
Sample sizes were based on previous experience and not on statistical power calculations. Subjects receiving at least one dose were included in safety analyses. Efficacy analyses were performed on subjects who completed all five study treatments (completed subjects). A secondary analysis was also conducted for all randomized subjects in Study CS866-445.
Changes from predose values were calculated at each time point. Differences among treatment groups were analyzed with an analysis of variance model, which included treatment, period, and sequence as fixed effects, and subjects nested within sequence as a random effect. Statistical comparisons were performed for all active treatments compared with placebo, and for each active treatment compared with the other active treatments.
For each of the five treatment groups (with all sequences combined) in both Study CS866-445 and Study CS866-448, the relationship between change in PRA from baseline to 24 h postdose and PRA baseline was assessed through scatterplots, linear regressions with PRA changes as the dependent variable, and PRA baseline as the independent variable, and through Pearson's correlation analyses.
Results
Subjects
In Study CS866-445, 24 subjects were randomized, 20 completed the study, and 4 discontinued due to positive drug screens. In Study CS866-448, 22 subjects were randomized, and 20 completed the study. One subject failed to return at week 3, and another had a positive drug screen.
Demographics and baseline characteristics are presented in Table 1 .
There was a high degree of consistency in predose PRA values in individual subjects over the 5-week period (data not shown). The coefficients of variation were 26% and 32% in the CS866-445 and CS866-448 studies, respectively. The PRA assay itself has a 7.6% interassay coefficient of variation. 17 The PRA levels (both the baseline and maximum levels attained during treatment in each study) were categorized by race (Table 2) . African American PRA levels averaged 50% and 64% of those of whites in Studies CS866-445 and CS866-448, respectively. Two of 24 and 10 of 22 subjects had baseline PRA levels Ͻ0.65 174 (54) 180 (54) 206 (57) 209 (57) BP ϭ blood pressure; PRA ϭ plasma renin activity; SD ϭ standard deviation. ng/mL/h in Studies CS866-445 and CS866-448, respectively.
PRA Responses to Ang II Receptor Antagonism
At all doses, olmesartan, valsartan, and irbesartan increased PRA (Fig. 1) at 2, 4, 8 , and 24 h. In Study CS866-445, in which PRA was also measured at 16 h, a diurnal nadir in PRA was detected in both the placebo and treatment groups (Fig. 1a) . The level of reactive PRA was higher for olmesartan 40 mg than for other active treatments. For olmesartan, there was a clear relationship between drug dose and PRA response. The mean change in PRA was significantly greater with the 40-mg dose than with the 20-mg dose at 8, 16, and 24 h. There was also an apparent dose relationship at 2 and 4 h, but statistical comparisons were not performed at these time points. For valsartan, there were no significant differences in mean change in PRA between the 80-mg and 160-mg doses at 8, 16, and 24 h or between valsartan 160 mg and 320 mg at 8 and 24 h (Fig. 1a,b) .
In Study CS866-445 (Fig. 2a ) at 24 h postdose (trough), ⌬PRA 24 was significantly greater than with placebo for both doses of olmesartan (P Ͻ .01 and Ͻ .001 for 20 and 40 mg, respectively) and for valsartan 160 mg (P Ͻ .05) but not for valsartan 80 mg. The ⌬PRA 24 was numerically higher with olmesartan 20 mg than with valsartan 80 mg for the primary analysis of all subjects who completed Study CS866-445, and it was significantly higher for the secondary analysis of all randomized subjects (data not shown), which included two additional subjects who received olmesartan 20 mg and valsartan 80 mg but not the other doses. The ⌬PRA 24 was highly correlated with the predose PRA value (Fig. 2b) Ϫ0.89, P Ͻ .0001) and for valsartan 160 mg (r ϭ 0.72, P Ͻ .01), and the slope was significantly greater for olmesartan 40 mg compared with valsartan 160 mg (P Ͻ .0001).
In Study CS866-448, in which the mean baseline PRA was lower (1.3 v 2.3 ng/mL/h), ⌬PRA 24 did not reach significance with valsartan 160 mg (Fig. 2c) but was significantly increased with valsartan 320 mg (P Ͻ .01), irbesartan 300 mg (P Ͻ .01), and olmesartan 40 mg (P Ͻ .0001). The ⌬PRA 24 was significantly higher with olmesartan 40 mg than with both doses of valsartan and irbesartan 300 mg (Fig. 2c) . The ⌬PRA 24 did not significantly differ between the valsartan 160 mg and 320 mg and irbesartan 300 mg groups. As in Study CS866-445, ⌬PRA 24 was highly correlated with the predose PRA for each ARB (r ϭ 0.84 for olmesartan 40 mg, r ϭ 0.68 for irbesartan 300 mg, r ϭ 0.69 for valsartan 160 mg, and r ϭ 0.96 for valsartan 320 mg) (Fig. 2d) . The slope of the regression line was significantly greater for olmesartan 40 mg (2.7) than for placebo (0.0, P Ͻ .0001), irbesartan 300 mg (1.1, P Ͻ .0001), valsartan 160 mg (1.2, P Ͻ .01), and valsartan 320 mg (1.57, P Ͻ .01). The slope of the regression line was significantly less for placebo than for irbesartan 300 mg (P Ͻ .01), valsartan 160 mg (P Ͻ .0001), and valsartan 320 mg (P Ͻ .0001), but it did not differ between the active drugs.
It should be noted that although study populations had similar demographics, approximately 25% of the subjects in Study CS866-445 and 60% in Study CS866-448 were African American. In addition, the mean baseline PRA was lower in CS866-448 (1.3 v 2.3 ng/mL/h), and the mean urinary sodium excretion was higher (206 v 174 mmol/day). African American subjects tended to have lower baseline PRA levels (Table 2 ) and a lower maximal PRA response to treatment, but the percent increase in maximal PRA was not different. In CS866-445, 2 of 6 African American subjects had suppressed PRA levels (PRA Ͻ0.65 ng/mL/h), whereas none of the other race groups had suppressed PRA levels. In CS 866-448, 8 of 14 African Americans and 2 of 5 white subjects had suppressed PRA levels, indicating that, in individual subjects, race is not an accurate discriminator of those with suppressed plasma renin levels.
Although subjects with suppressed PRA levels responded to ARB administration with a rise in PRA (Table 2) , a comparison between Figs. 3a and 3b and Figs. 3c and 3d shows that the rise was very small in absolute terms compared with the response of subjects whose PRA was not suppressed at baseline.
Urinary Aldosterone Responses to Ang II Receptor Antagonism
Mean 24-h UAE rates (Table 3) were significantly reduced compared with placebo by both doses of olmesartan and irbesartan and by valsartan 320 mg but not by valsartan 80 mg. Valsartan 160 mg suppressed UAE in Study CS866-445 but not in Study CS866-448, consistent with the PRA changes. In Study CS866-445, there was no significant difference in mean UAE between olmesartan doses, but valsartan 160 mg and both olmesartan doses reduced UAE more than did valsartan 80 mg. In Study CS866-448, there were no significant differences in 24-h UAE rates between active treatment groups.
BP Responses to Ang II Receptor Antagonism
Blood-pressure values predose and at 2, 4, 8, 16, and 24 h postdose are shown in Table 4 . As expected in studies of normotensive subjects, BP changes were small and not significantly different for any of the ARBs. No correlations were found between BP changes and PRA increases for any of the drug regimens or in the groups as a whole. Interestingly, during placebo treatment, both systolic and diastolic pressures were higher at 16 h (the nadir for PRA) than at 2, 4, 8, and 24 h, a pattern that was also observed during each dose of ARB.
Safety
The majority of treatment-emergent AEs were mild, and the incidence was similar across all treatments. No subject experienced a serious AE, and none discontinued the studies because of AEs.
Twelve subjects reported one or more clinical treatment-emergent AEs during Study CS866-445. The most frequent AE overall was headache, which was also the AE most often reported as being possibly related to the study drugs.
In Study CS866-448, six subjects reported one or more treatment-emergent AEs. All were considered to be unrelated or unlikely to be related to the study drugs, except for a possibly related balance disorder and disturbance in attention in one subject during treatment with valsartan 160 mg. Both AEs were mild and resolved 1 day later without treatment.
Discussion
The results of these studies demonstrate that, in healthy normal subjects, single oral doses of olmesartan 20 mg and 40 mg, valsartan 320 mg, and irbesartan 300 mg caused sustained increases in ambulatory plasma renin levels for 24 h, whereas valsartan 80 mg did not. Valsartan 160 mg caused a significant increase in PRA at 24 h from baseline level in the first study, in which baseline PRA levels were higher. The PRA increases were dose-related for olmesartan but not for valsartan, ie, similar to the results of a previous study in which dose-dependent PRA increases with valsartan were not observed until after 8 days of dosing. 8 It is unclear whether olmesartan 20 mg has a more sustained effect on PRA than valsartan 80 mg, because the difference reached significance only when all randomized subjects were included in the analysis. Olmesartan 40 mg caused a larger increase in mean PRA at 24 h than did irbesartan 300 mg or valsartan 320 mg, the highest recommended daily doses of these three agents. 18 -20 The differences among drugs would not have been predicted from the drugs' pharmacokinetic properties and may relate to their kinetics and affinity for AT 1 receptor binding. 21 Reductions in mean 24-h UAE rates were consistent with the PRA data, insofar as UAE fell only in those studies in which the PRA was still increased after 24 h. This may indicate that the rate of UAE rebounds to above baseline levels once the effect of the blocker has worn off.
Many previous studies demonstrated that PRA increases reactively in response to blockade of the RAS, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 15, 16 but in most previous studies, plasma renin was measured under controlled conditions of posture or diet. Other studies showed that patients with hypertension and with low plasma renin levels have lower absolute increases in PRA, 22, 23 but, again, these studies were carried out under controlled conditions. However, in the current studies, similar patterns of renin reactivity were observed in normal subjects when blood samples were drawn under less controlled conditions from quietly seated ambulatory subjects, similar to conditions normally found in a clinic or doctor's office. Thus, dietary sodium was not controlled, normal ambulation was allowed, and blood was drawn in a quietly seated position. Despite this lack of restrictions, baseline PRA levels were reproducible for each subject. The pattern of PRA responses was similar to those of previous studies and was reproducible in the two studies reported here, making the results more relevant to normal living conditions. The same could be said for the heterogeneity of the population in terms of race, sex, and baseline PRA. The fact that clear and statistically significant differences were seen among the drugs and regimens attests to the robust nature of these findings.
Most recent studies did not analyze the renin response in relation to baseline PRA levels. Azizi et al 9 showed that the plasma renin concentration (they termed it "active renin") increased to quite high levels in normal subjects whose renin had been previously suppressed by a high-salt diet, especially during combined blockade with an angiotensin-converting enzyme inhibitor and an ARB. Although their subjects were said to have "low renin concentrations," the plasma renin levels of their normal subjects were not "low" according to our criteria. Thus, their baseline active renin averaged 10 pg/mL (95% confidence interval, 7 to 17 pg/mL), 9 equivalent to our PRA of 2 ng/mL/h. 24 Our cutoff for low renin is Ͻ0.65 ng/mL/h, equivalent to 3.3 pg/mL in their assay. Differences in demographics between their subjects and ours may explain the higher preponderance of low-renin subjects in our studies. They studied young men 18 to 35 years of age with an average BP of 120/63 mm Hg. Although, in our two studies, the subjects had a lower sodium excretion rate (180 and 209 mmol/day, respectively) compared with their 350 mmol/day, our higher predominance of truly lowrenin subjects is most likely due to slightly higher diastolic BPs (79 and 76 v 63 mm Hg, respectively) and our inclusion of older normal subjects 25 (averaging 37 and 41 years of age, respectively), and 30% women in both studies (Studies CS866-445 and CS886-448, respectively), and 25% and 60% African Americans in Studies CS866-445 and CS866-448, respectively. 25, 26 All of these differences would increase the likelihood of encountering subjects with low plasma renin levels. 25 The subjects with suppressed baseline renin levels (PRA Ͻ0.65 ng/mL/h) had similar percent increases in PRA but much smaller absolute increases in response to ARB administration. Altogether, there was a highly positive correlation between baseline PRA and ⌬PRA 24 for all doses in which PRA remained significantly elevated at 24 h.
For all drugs and doses in Study CS866-445, PRA was lower at 16 h (corresponding to around midnight) than at 24 h. It is well documented that there is a diurnal variation in plasma renin levels, with their nadir occurring during the night. 27 The BP data from this study indicate that in normal subjects who are kept awake and are encouraged to ambulate for 15 min at midnight, systolic BP tends to be higher than at other times during the day. This higher BP may contribute to the nightly suppression of the ambulatory plasma renin level. This pattern of renin and BP response occurred even when renin secretion was stimulated by AT 1 receptor blockade and appeared to reduce the ability to detect an effect of AT 1 receptor blockade on PRA. In fact, at 16 h, ⌬PRA was significantly increased only for olmesartan 40 mg. There are several limitations to these studies. They were conducted in normal subjects and not in patients with hypertension. Although this is a well-established procedure for evaluating differences between the pharmacologic properties of various drugs, the results do not necessarily predict BP responses to these agents in a hypertensive population. As a group, normal subjects tend to have more reactive plasma renin levels than do subjects with hypertension in response to RAS blockade. Moreover, the counter-responses that help maintain normal BP in healthy subjects may be different in patients with hypertension exposed to the same drug. To determine clinical significance, these studies should be repeated in patients with hypertension. The fact that these were single-dose studies is also a limitation. Whether the same results would be obtained with multiple doses is a matter for further study.
In conclusion, the studies described here demonstrate that ambulatory plasma renin measurements in normal subjects can be used to assess the efficacy of angiotensin receptor blockade over 24 h in subjects studied once weekly over a 5-week period without any dietary restrictions. Olmesartan treatment caused dose-dependent increases in PRA, and the highest approved daily dose of olmesartan (40 mg) consistently induced more prolonged AT 1 receptor blockade than all doses of valsartan and irbesartan examined. The clinical implications of these findings, while intriguing, will need to be evaluated in patients with hypertension.
